




RealRate

# PHARMACEUTICAL 2018

Viracta Therapeutics Inc.  
Rank 240 of 342





# PHARMACEUTICAL 2018

Viracta Therapeutics Inc.  
Rank 240 of 342



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.6%, being 38% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	32,933
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,678
Liabilities, Non-Current	0
Other Assets	1,381
Other Compr. Net Income	15
Other Expenses	1,396
Other Liabilities	0
Other Net Income	357
Other Revenues	669
Property and Equipment	20
Research and Development	21,540
Selling, General and Administrative Expense	13,548

Output Variable	Value in 1000 USD
Assets	34,334
Liabilities	12,678
Expenses	36,484
Revenues	669
Stockholders Equity	21,656
Net Income	-35,458
Comprehensive Net Income	-35,450
Economic Capital Ratio	7.6%